MAPT and Alzheimer disease: Importantly, our current data indicating aggregated Tau as activator of NLRP3–ASC inflammasome further lend support to this hypothesis extending a potential role of NLRP3–ASC inflammasome beyond AD and primary Tauopathies to a variety of neurodegenerative disorders characterized by aggregating proteins [41].